home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.030 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names ↗

November 29, 2023

As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.

Via InvestorPlace

Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year ↗

November 22, 2023

Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems.

Via InvestorPlace

The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗

November 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Via InvestorPlace

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗

November 20, 2023

Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?

Via The Motley Fool

A Preview Of Editas Medicine's Earnings ↗

November 02, 2023

Via Benzinga

Analyst Ratings for Editas Medicine ↗

October 18, 2023

Via Benzinga

Is Editas Stock a Buy Now? ↗

October 07, 2023

Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?

Via The Motley Fool

3 Long-Term Growth Stocks Analysts Are Bullish On ↗

November 16, 2023

Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.

Via InvestorPlace

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

November 03, 2023

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

Via Benzinga

Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗

November 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

November 03, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

November 02, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2023 ↗

November 03, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Via Benzinga

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

October 27, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 ↗

October 18, 2023

Via Benzinga

1 Risky Biotech Stock to Consider Buying, and 1 to Avoid ↗

October 18, 2023

Both are in a race against time to commercialize a medicine before cash runs out.

Via The Motley Fool

Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗

October 17, 2023

Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 17, 2023

It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!

Via InvestorPlace

NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 17, 2023

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

October 16, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things ↗

October 05, 2023

It's key to understand the resources it will take to deliver a company's pipeline.

Via The Motley Fool

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics ↗

October 02, 2023

The better of the pair should be able to beat Bluebird Bio.

Via The Motley Fool

Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 29, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

Via Benzinga

Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock ↗

September 29, 2023

Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com